Literature DB >> 20179241

Does lapatinib work against HER2-negative breast cancers?

Ingrid A Mayer1, Carlos L Arteaga.   

Abstract

Aberrant growth factor receptor signaling can augment or suppress estrogen receptor (ER) function in hormone-dependent breast cancer cells and lead to escape from anti-estrogen therapy. Interruption of HER2/ER cross-talk with lapatinib can restore sensitivity to anti-estrogens and thus, should be investigated in combination with endocrine therapy in patients with ER+/HER2-negative breast cancers.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20179241      PMCID： PMC3448974          DOI： 10.1158/1078-0432.CCR-09-3223

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  11 in total

1.  A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer.

Authors:  Wenle Xia; Sarah Bacus; Priti Hegde; Intisar Husain; Jay Strum; Leihua Liu; Georgina Paulazzo; Ljuba Lyass; Patricia Trusk; Jason Hill; Jennifer Harris; Neil L Spector
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-08       Impact factor: 11.205

2.  Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells.

Authors:  A S Oh; L A Lorant; J N Holloway; D L Miller; F G Kern; D El-Ashry
Journal:  Mol Endocrinol       Date:  2001-08

3.  The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer.

Authors:  D W Rusnak; K Affleck; S G Cockerill; C Stubberfield; R Harris; M Page; K J Smith; S B Guntrip; M C Carter; R J Shaw; A Jowett; J Stables; P Topley; E R Wood; P S Brignola; S H Kadwell; B R Reep; R J Mullin; K J Alligood; B R Keith; R M Crosby; D M Murray; W B Knight; T M Gilmer; K Lackey
Journal:  Cancer Res       Date:  2001-10-01       Impact factor: 12.701

4.  Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors.

Authors:  Chad J Creighton; Amy M Hilger; Shalini Murthy; James M Rae; Arul M Chinnaiyan; Dorraya El-Ashry
Journal:  Cancer Res       Date:  2006-04-01       Impact factor: 12.701

5.  Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.

Authors:  Stephen Johnston; John Pippen; Xavier Pivot; Mikhail Lichinitser; Saeed Sadeghi; Veronique Dieras; Henry Leonidas Gomez; Gilles Romieu; Alexey Manikhas; M John Kennedy; Michael F Press; Julie Maltzman; Allison Florance; Lisa O'Rourke; Cristina Oliva; Steven Stein; Mark Pegram
Journal:  J Clin Oncol       Date:  2009-09-28       Impact factor: 44.544

6.  Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.

Authors:  Bella Kaufman; John R Mackey; Michael R Clemens; Poonamalle P Bapsy; Ashok Vaid; Andrew Wardley; Sergei Tjulandin; Michaela Jahn; Michaela Lehle; Andrea Feyereislova; Cédric Révil; Alison Jones
Journal:  J Clin Oncol       Date:  2009-09-28       Impact factor: 44.544

Review 7.  Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance.

Authors:  Grazia Arpino; Lisa Wiechmann; C Kent Osborne; Rachel Schiff
Journal:  Endocr Rev       Date:  2008-01-23       Impact factor: 19.871

8.  Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.

Authors:  Mitch Dowsett; Craig Allred; Jill Knox; Emma Quinn; Janine Salter; Chris Wale; Jack Cuzick; Joan Houghton; Norman Williams; Elizabeth Mallon; Hugh Bishop; Ian Ellis; Denis Larsimont; Hironobu Sasano; Pauline Carder; Antonio Llombart Cussac; Fiona Knox; Valerie Speirs; John Forbes; Aman Buzdar
Journal:  J Clin Oncol       Date:  2008-01-28       Impact factor: 44.544

9.  Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy.

Authors:  Elisabetta Munzone; Giuseppe Curigliano; Andrea Rocca; Giuseppina Bonizzi; Giuseppe Renne; Aron Goldhirsch; Franco Nolè
Journal:  Breast Cancer Res       Date:  2005-12-07       Impact factor: 6.466

10.  Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance.

Authors:  Alexandra F Leary; Suzanne Drury; Simone Detre; Sunil Pancholi; Anne E Lykkesfeldt; Lesley-Ann Martin; Mitch Dowsett; Stephen R D Johnston
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531
View more
  6 in total

Review 1.  Treatment of HER2-positive breast cancer: current status and future perspectives.

Authors:  Carlos L Arteaga; Mark X Sliwkowski; C Kent Osborne; Edith A Perez; Fabio Puglisi; Luca Gianni
Journal:  Nat Rev Clin Oncol       Date:  2011-11-29       Impact factor: 66.675

2.  Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance.

Authors:  Gladys Morrison; Xiaoyong Fu; Martin Shea; Sarmistha Nanda; Mario Giuliano; Tao Wang; Teresa Klinowska; C Kent Osborne; Mothaffar F Rimawi; Rachel Schiff
Journal:  Breast Cancer Res Treat       Date:  2014-02-20       Impact factor: 4.872

3.  BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib.

Authors:  M F E Godinho; J D Wulfkuhle; M P Look; A M Sieuwerts; S Sleijfer; J A Foekens; E F Petricoin; L C J Dorssers; T van Agthoven
Journal:  Br J Cancer       Date:  2012-08-14       Impact factor: 7.640

4.  Identification of potential new treatment response markers and therapeutic targets using a Gaussian process-based method in lapatinib insensitive breast cancer models.

Authors:  Tapesh Santra; Sandra Roche; Neil Conlon; Norma O'Donovan; John Crown; Robert O'Connor; Walter Kolch
Journal:  PLoS One       Date:  2017-05-08       Impact factor: 3.240

5.  Development of a test that measures real-time HER2 signaling function in live breast cancer cell lines and primary cells.

Authors:  Yao Huang; David J Burns; Benjamin E Rich; Ian A MacNeil; Abhijit Dandapat; Sajjad M Soltani; Samantha Myhre; Brian F Sullivan; Carol A Lange; Leo T Furcht; Lance G Laing
Journal:  BMC Cancer       Date:  2017-03-16       Impact factor: 4.430

6.  Trichostatin A suppresses EGFR expression through induction of microRNA-7 in an HDAC-independent manner in lapatinib-treated cells.

Authors:  Chih-Yen Tu; Chia-Hung Chen; Te-Chun Hsia; Min-Hsiang Hsu; Ya-Ling Wei; Meng-Chieh Yu; Wen-Shu Chen; Ke-Wei Hsu; Ming-Hsin Yeh; Liang-Chih Liu; Yun-Ju Chen; Wei-Chien Huang
Journal:  Biomed Res Int       Date:  2014-02-23       Impact factor: 3.411
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.